- Trials with a EudraCT protocol (138)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (7)
138 result(s) found for: Vancomycin.
Displaying page 1 of 7.
EudraCT Number: 2015-003171-29 | Sponsor Protocol Number: VANCO-PK/IM_E:005/2015 | Start Date*: 2015-12-17 |
Sponsor Name:Universitätsklinikum Tübingen | ||
Full Title: The correlation between vancomycin AUC and trough levels during intermittent dosing of vancomycin and plateau levels during continuous infusion - Pharmacokinetic evaluation of Vancomycin and the in... | ||
Medical condition: In patients who receive an antibiotic therapy with vancomycin i.v. (because of an infection) blood-, urine and stool samples are taken at certain time points and data on the pharmakokinetic of vanc... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-003670-31 | Sponsor Protocol Number: BC-10433 | Start Date*: 2021-09-22 |
Sponsor Name:Ghent University Hospital | ||
Full Title: Impact of Model-Informed Precision Dosing of Vancomycin in Adults: A randomized, controlled clinical trial | ||
Medical condition: Gram positive infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000203-89 | Sponsor Protocol Number: NeoVanc | Start Date*: 2016-07-18 | |||||||||||
Sponsor Name:Fondazione PENTA Onlus | |||||||||||||
Full Title: Multi-centre, randomised, open label, phase IIb study to compare the efficacy, safety and pharmacokinetics (PK) of an optimised dosing to a standard dosing regimen of vancomycin in neonates and inf... | |||||||||||||
Medical condition: Neonatal late onset sepsis | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) IT (Prematurely Ended) EE (Prematurely Ended) ES (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005349-29 | Sponsor Protocol Number: CSP.XEL1005 | Start Date*: 2016-02-15 |
Sponsor Name:Xellia d.o.o. | ||
Full Title: Plasma levels of crystalline degradation product 1 (CDP-1) in vancomycin- treated patients with normal or impaired renal function | ||
Medical condition: Not applicable: medical conditions or diseases will not be investigated in this trial. In this trial pharmacokinetic parameters of vancomycin and its degradation products will be determined in bl... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HR (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2010-022348-18 | Sponsor Protocol Number: MCBC134ADE02T | Start Date*: 2010-11-08 |
Sponsor Name:Heart- and Diabetescenter NRW | ||
Full Title: Application of Daptomycin in MRSA infected diabetic foot in comparison to vancomycin treatment | ||
Medical condition: Patients eligible for this study suffer from diabetic foot infections. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-018034-11 | Sponsor Protocol Number: 2010vanco.psc | Start Date*: 2013-04-29 |
Sponsor Name:Karolinska Institutet | ||
Full Title: Open pilot study of treatment with vancomycin to children and adolescents with primary sclerosing cholangitis | ||
Medical condition: Primary Sclerosing Cholangitis (PSC) is a progressive disease of the biliary system which might lead to increased risk of cholangiocancer. PSC constitutes a common indication for adult liver transp... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000010-38 | Sponsor Protocol Number: PAEDMED_v1.0 | Start Date*: 2018-03-20 |
Sponsor Name:Department of Clinical Pharmacology/Medical University of Vienna | ||
Full Title: Development of intravascular microdialysis as a tool for therapeutic drug monitoring in children. | ||
Medical condition: cohort A: We will administer a single dose of vancomycin, cefuroxime or gentamicin to healthy volunteers. The administration of the antibiotics in cohort A is for study purposes only. cohort B: We... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18, Adults | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-004538-40 | Sponsor Protocol Number: BC-5429 | Start Date*: 2020-11-20 |
Sponsor Name:Ghent University Hospital | ||
Full Title: A multicentric randomised controlled clinical trial to study the impact of bedside model-informed precision dosing of vancomycin in critically ill children. | ||
Medical condition: Gram positive infection | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004814-84 | Sponsor Protocol Number: CS/2016/01 | Start Date*: 2016-05-18 |
Sponsor Name:Sint Antonius Hospital | ||
Full Title: Individualized dosing of aminoglycosides, quinolones and glycopeptide antibiotics in (morbidly) obese patients | ||
Medical condition: Morbid obesity | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003835-28 | Sponsor Protocol Number: APHP210089 | Start Date*: 2022-02-17 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS | |||||||||||||
Full Title: Prevention of C. difficile infections with oral vancomycin in patients treated for allogeneic hematopoietic stem cell transplantation, a double-blind, randomized, placebo-controlled trial ” VANCALLO | |||||||||||||
Medical condition: Patients hospitalized for an allogeneic hematopoietic stem cell transplant | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004676-37 | Sponsor Protocol Number: GD3-170-302 | Start Date*: 2005-04-27 | |||||||||||
Sponsor Name:Genzyme Europe BV | |||||||||||||
Full Title: A randomized, double-blind study of GT267-004 versus vancomycin, and GT267-004 versus metronidazole, in patients with C.difficile-associated diarrhea | |||||||||||||
Medical condition: C. difficile-associated diarrhea (CDAD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) DE (Completed) CZ (Completed) DK (Completed) AT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000508-40 | Sponsor Protocol Number: 2819-CL-0202 | Start Date*: 2014-11-18 | |||||||||||
Sponsor Name:Astellas Pharma Europe B.V. | |||||||||||||
Full Title: A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid ... | |||||||||||||
Medical condition: Treatment of enterocolitis caused by Clostridium difficile | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) SK (Completed) PL (Completed) IT (Completed) ES (Completed) HU (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002904-13 | Sponsor Protocol Number: 0019 | Start Date*: 2006-11-01 | |||||||||||
Sponsor Name:Theravance, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Patients with Infec... | |||||||||||||
Medical condition: Hospital-Acquired Pneumonia with a Focus on Patients with Infections Due to Methicillin-Resistant Staphylococcus aureus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) ES (Completed) SI (Completed) SK (Completed) LT (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000608-14 | Sponsor Protocol Number: 1.0/170119 | Start Date*: Information not available in EudraCT |
Sponsor Name:Tartu University Hospital | ||
Full Title: Prospective validation of individualized Bayesian dose optimization tool DosOpt for Vancomycin treatment in neonates. | ||
Medical condition: In neonatal population wide inter-and intra-individual variability of pharmacokinetics makes extremely difficult to ensure optimal exposure of vancomycin with standard regimens. On average >50% of ... | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: EE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-002902-31 | Sponsor Protocol Number: 0015 | Start Date*: 2005-11-09 | |||||||||||
Sponsor Name:Theravance, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Patients with Infec... | |||||||||||||
Medical condition: Hospital-Acquired Pneumonia with a Focus on Patients with Infections Due to Methicillin-Resistant Staphylococcus aureus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) CZ (Completed) BE (Completed) DE (Completed) MT (Completed) SK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002096-29 | Sponsor Protocol Number: iVRCT | Start Date*: 2015-07-20 | ||||||||||||||||
Sponsor Name:Speising Orthopaedic Hospital Vienna | ||||||||||||||||||
Full Title: Application of Intrawound Vancomycin Powder in Spinal Fusion Surgery to Reduce Postoperative Surgical Site Infections - A Prospective Randomized Controlled Trial | ||||||||||||||||||
Medical condition: Postoperative surgical site infections (deep and superficial) after spinal fusion surgery | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004291-12 | Sponsor Protocol Number: 101.1.C.004 | Start Date*: 2008-08-18 | |||||||||||
Sponsor Name:Optimer Pharmaceuticals, Inc. | |||||||||||||
Full Title: A multi-national, multi-centre, double-blind, randomised, parallel group study to compare the safety and efficacy of 200mg PAR-101 taken q12h with 125mg Vancomycin taken q6h for ten days in subject... | |||||||||||||
Medical condition: Clostridium difficile associated diarrhoea (CDAD) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) BE (Completed) ES (Completed) FR (Completed) SE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000258-12 | Sponsor Protocol Number: 230189 | Start Date*: 2014-10-15 | |||||||||||
Sponsor Name:Orthopedic Research in Aarhus | |||||||||||||
Full Title: Pharmacokinetics of vancomycin in cancellous and cortical bone obtained by microdialysis | |||||||||||||
Medical condition: Orthopedic infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001642-10 | Sponsor Protocol Number: SMT19969/C005 | Start Date*: 2019-03-13 | |||||||||||
Sponsor Name:Summit (Oxford) Limited | |||||||||||||
Full Title: A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of ridinilazole (200 mg, bid) for 10 days with vancomycin (125 mg, qid) for 10 days in the treatment ... | |||||||||||||
Medical condition: Clostridium difficile infection (CDI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LV (Completed) LT (Completed) BE (Prematurely Ended) DE (Completed) CZ (Completed) ES (Ongoing) FR (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004531-36 | Sponsor Protocol Number: MU1646 | Start Date*: 2018-09-03 |
Sponsor Name:Ardeypharm GmbH | ||
Full Title: Escherichia coli strain Nissle 1917 - Suspension for treatment of patients with Clostridium difficile associated diarrhoea | ||
Medical condition: Clostridium difficile associated diarrhoea (CDAD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
